Mr. William Stilley serves as President, Chief Executive Officer and Board Member at ADial Pharmaceuticals. He is an Angel Investor. Prior to joining ADial Pharmaceuticals, LLC, he was the Vice President, Business Development & Strategic Projects at PGxHealth, LLC, a division of Clinical Data, Inc. (NASDQ CLDA). At PGxHealth, Mr. Stilley worked on licensing and M&A transactions and was involved in management of Phase III clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for Stedivaze's Phase III clinical trials. Previously, Mr. Stilley was the COO and CFO of Adenosine Therapeutics, LLC where he ran the internal operations of the company, including research and development, and all financing activity until Adenosine Therapeutics was acquired by PGxHealth in August 2008. Mr. Stilley also worked closely with the CEO on all of the company's major transactions. Mr. Stilley has advised both public and private companies on financing and M&A transactions, has been the interim CFO of a public company and the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps. Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He currently guest lectures at the Darden School of Business in two courses on the management of life science companies and serves on the Board of Virginia BIO, the statewide biotechnology organization.